In vivo anti-inflammatory effects of the M20 IL-1 Inhibitor: II. Effects on serum reactants |
| |
Authors: | Vivian Barak Raphael Gorodetsky Josef Weidenfeld David Peritt Peter Yanai Tal Halperin Abraham J Treves |
| |
Institution: | (1) Immunology Laboratory, Oncology Department, Hadassah University Hospital, Jerusalem, Israel |
| |
Abstract: | We have previously described an IL-1 Inhibitor derived from the M20 myelomoncytic cell line. This line also secretes several molecules of IL-1. We have shown that this factor is specific to IL-1in vitro, as well asin vivo. In vitro IL-1 induced proliferative responses of mouse thymocytes, human T cells and fibroblasts and IL-1 stimulated PGE2 secretion from fibroblasts, were all inhibited by the M20 IL-1 Inhibitor.In vivo, the IL-1 Inhibitor reduced parameters of acute inflammation such as fever, leukocytosis and local inflammation. This study describes additional effects of the M20 IL-1 Inhibitor on inflammatory serum reactants. Levels of corticosterone and fibrinogen were increased by injection of IL-1, and decreased by the IL-1 Inhibitor. IL-1 reduced zinc and iron plasma levels and elevated copper plasma levels. The M20 IL-1 Inhibitor reversed these changes in a dose dependent manner. Similar effects produced by IL-6 and TNF were unaffected by the M20 IL-1 Inhibitor. Our results indicate that the M20 IL-1 Inhibitor acts specifically on IL-1 induced responsesin vivo. Therefore we conclude that this IL-1 Inhibitor has a great potential as an anti-inflammatory agent.Abbreviations IL-1
Interleukin 1
- IL-6
Interleukin 6
- IL-1ra
Interleukin 1 receptor antagonist
- TNF
tumor necrosis factor |
| |
Keywords: | In vivo inflammation IL-1 M20 IL-1 Inhibitor |
本文献已被 SpringerLink 等数据库收录! |
|